| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Articles |
Department of Nephrology, University Hospital of Lund, Sweden.
OBJECTIVE: To report our first clinical experience with a new continuous ambulatory peritoneal dialysis (CAPD) fluid (PD-Bio), which is nearly devoid of glucose degradation products and has a higher pH (6.3) than conventional peritoneal dialysis (PD) solutions, and to discuss in general terms some acute and long-term effects of conventional acidic solutions containing glucose degradation products. DESIGN: 1) Pilot study on 4 patients investigated using a modified peritoneal equilibration test (PET) and cytobiology parameters. 2) Computer simulation study, assuming that conventional acidic solutions cause vasodilatation and recruitment of capillary surface area initially (during 0-60 minutes) in a PD dwell. PATIENTS: Four stable CAPD patients were chosen in an open cross-over study. After a period of three months using conventional PD fluid, the patients were switched to three months on the new PD fluid. RESULTS: Cancer antigen 125 increased significantly, and patients with discomfort/infusion pain during the control period improved during the period with the new fluid. No significant changes were observed in mass-transfer coefficients or drained volumes with the new solution. PH in the effluent dialysis was, however, higher for PD-Bio at all times during a two-hour dwell. In the computer simulation study, a less acidic solution caused an initially lower rate of glucose dissipation and improved ultrafiltration (UF) after a four-hour dwell, as compared to a conventional PD solution. CONCLUSIONS: A new, differently produced, less toxic and less acidic PD fluid (PD-Bio) seems to be better tolerated than a conventional acidic solution with respect to discomfort/infusion pain. Theoretically, neutralized solutions should show slightly improved UF profiles over conventional acidic solutions, according to the computer simulation analysis. Furthermore, it is speculated that a neutral, less acidic, less toxic fluid would cause less interstitial-mesothelial alterations and less impairment of UF capacity than conventional solutions during long-term CAPD.
This article has been cited by other articles:
|
|
 |
|
  S. Haas, C. P. Schmitt, K. Arbeiter, K.-E. Bonzel, M. Fischbach, U. John, A.-K. Pieper, T. P. Schaub, J. Passlick-Deetjen, O. Mehls, et al. Improved Acidosis Correction and Recovery of Mesothelial Cell Mass with Neutral-pH Bicarbonate Dialysis Solution among Children Undergoing Automated Peritoneal Dialysis J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2632 - 2638. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mortier, A. S. De Vriese, J. Van de Voorde, T. P. Schaub, J. Passlick-Deetjen, and N. H. Lameire Hemodynamic Effects of Peritoneal Dialysis Solutions on the Rat Peritoneal Membrane: Role of Acidity, Buffer Choice, Glucose Concentration, and Glucose Degradation Products J. Am. Soc. Nephrol., February 1, 2002; 13(2): 480 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Gokal Peritoneal Dialysis in the 21st Century: An Analysis of Current Problems and Future Developments J. Am. Soc. Nephrol., January 1, 2002; 13(90001): S104 - 115. [Full Text] [PDF]
|
|
|
|
|
|
J. WITOWSKI, J. WISNIEWSKA, K. KORYBALSKA, T. O. BENDER, A. BREBOROWICZ, G. M. GAHL, U. FREI, J. PASSLICK-DEETJEN, and A. JORRES Prolonged Exposure to Glucose Degradation Products Impairs Viability and Function of Human Peritoneal Mesothelial Cells J. Am. Soc. Nephrol., November 1, 2001; 12(11): 2434 - 2441. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
